文献速递骨质疏松与代谢性骨病

地塞米松辅助管理首次唑来膦酸输注后急性期反应

Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
PubMed 文献 · Osteoporos Int · 2020-10-28

这项研究纳入96例首次接受唑来膦酸输注的骨质疏松患者,比较单用对乙酰氨基酚(对照组58例)与对乙酰氨基酚联合地塞米松(研究组38例)对急性期反应的影响。结果显示研究组任何急性期反应的发生率和严重程度显著低于对照组,仅肌痛发生率和评分显著降低,且研究组再次输注唑来膦酸的依从性显著更高。

要点

  • 对乙酰氨基酚联合地塞米松可显著降低首次唑来膦酸输注后急性期反应的发生率和严重程度。
  • 两组间仅肌痛的发生率和评分在研究组显著降低。
  • 研究组再次输注唑来膦酸的依从性显著高于对照组。

核心结论

  • 地塞米松联合对乙酰氨基酚可有效显著降低首次唑来膦酸输注后急性期反应的发生率和严重程度,尤其是肌痛,并提高再次输注的依从性。

研究设计与样本

  • 研究纳入96例首次接受唑来膦酸输注的骨质疏松患者,分为对照组58例(单用对乙酰氨基酚)和研究组38例(对乙酰氨基酚联合地塞米松),输注后2周通过电话访谈评估急性期反应。

主要发现

  • 对照组任何急性期反应的发生率显著高于研究组(67% vs 34%,p=0.003),严重程度评分也显著高于研究组(0.69±0.50 vs 0.34±0.48,p=0.001)。
  • 在各类急性期反应中,仅肌痛的发生率和评分在对照组显著高于研究组。
  • 多因素分析显示,既往使用骨质疏松药物和参与研究组与任何急性期反应或肌痛的发生呈负相关;高龄显著增加肌痛;研究组参与者肌痛严重程度显著降低。
  • 研究组再次输注唑来膦酸的依从性显著高于对照组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Acute phase response (APR), including myalgia, influenza-like symptoms, headache, arthralgia, and pyrexia, is the most common adverse reaction to initial zoledronic acid infusion. Dexamethasone plus acetaminophen is effective in significantly reducing the incidence and severity of APR. INTRODUCTION: Acute phase response (APR), including myalgia, influenza-like symptoms, headache, arthralgia, and pyrexia, is due to immunomodulatory actions and is the most common adverse reaction to zoledronic acid (ZOL). The aims of our study were to compare the differences between acetaminophen and dexamethasone plus acetaminophen on the incidence and severity of APRs and to clarify the clinical factors related to APR with initial ZOL infusion. METHODS: Patients with osteoporosis receiving their first ZOL infusion (N = 96) were assigned into two groups and given either acetaminophen (58 patients, control group) or acetaminophen plus dexamethasone (38 patients, study group). APRs were assessed through telephone interviews 2 weeks later post-infusion. Clinical, demographic, and serologic data were recorded. RESULTS: There was a significant increase in the incidence and severity of any APR in the control group than the study group (67% vs. 34%, p = 0.003; 0.69 ± 0.50 vs. 0.34 ± 0.48, p = 0.001). Among the APRs, only myalgia incidence and score were significantly higher in the control group than in the study group. Multivariate analysis demonstrated that previous use of osteoporosis medication and participation in the study group was negatively related to the occurrence of any APR or myalgia. Advanced age was shown to significantly increase myalgia. Study group participants had significantly reduced severity of myalgia. The adherence for redosing ZOL was significantly higher in the study group. CONCLUSION: Dexamethasone plus acetaminophen is effective in significantly reducing the incidence and severity of APR, especially myalgia, and increasing adherence following initial ZOL infusion.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chen FP, Fu TS, Lin YC, et al. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion. Osteoporos Int. 2020. PMID: 33113007. doi:10.1007/s00198-020-05653-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。